08:00 , Nov 12, 2015 |  BC Innovations  |  Targets & Mechanisms

Breaking down beliefs

Researchers at the Genentech Inc. unit of Roche are challenging the widely held belief that the blood-brain barrier (BBB) breaks down in Alzheimer's disease to cause neurodegeneration and acts as a gateway for delivery of...
01:56 , Feb 19, 2015 |  BC Extra  |  Company News

Management tracks

Lycera Corp. (Ann Arbor, Mich.) named Paul Sekhri president, CEO and director, effective immediately. Sekhri was SVP of integrated care at Sanofi (Euronext:SAN; NYSE:SNY). Pharming Group N.V. (Euronext:PHARM) hired Perry Calias as CSO, effective immediately....
08:00 , Jan 15, 2015 |  BC Innovations  |  Finance

Consortia cross-talk

There's no doubt that the consortium model is here to stay, but the challenge now is to avoid creating a bureaucracy of committees with duplicate missions and redundancies of effort. The answer might be a...
08:00 , Jan 12, 2015 |  BC Week In Review  |  Company News

BBB Therapeutics management update

BBB Therapeutics B.V. , Leiden, the Netherlands   Business: Drug delivery, Cancer, Neurology   Resigned: Anders Harfstrand as CEO  ...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Company News

BBB Therapeutics management update

BBB Therapeutics B.V. , Leiden, the Netherlands   Business: Drug delivery, Cancer, Neurology   Hired: Ferdinand Massari as CMO, formerly SVP and CMO of ImmusanT Inc.   Transitioned: Pericles Calias to CSO from SVP of...
07:00 , Sep 29, 2014 |  BC Week In Review  |  Clinical News

2B3-201: Phase I data

A double-blind, crossover, Dutch Phase I trial in 18 healthy male volunteers showed that single ascending doses of up to 450 mg 2B3-201 were well tolerated with no serious adverse events reported. Subjects received an...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Company News

to-BBB management update

to-BBB technologies B.V. , Leiden, the Netherlands   Business: Drug delivery, Cancer, Neurology   Hired: Anders Harfstrand as CEO, formerly president and CEO of Humabs BioMed S.A. ; he succeeds interim CEO Leonard Kruimer, who...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Company News

Prosensa Holding N.V management update

Prosensa Holding N.V . (NASDAQ:RNA), Leiden, the Netherlands   Business: Musculoskeletal, Neurology   Hired: Willem van Weperen as chief commercial officer, a newly created position, formerly CEO of to-BBB technologies B.V.  ...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Financial News

to-BBB technologies B.V completes venture financing

to-BBB technologies B.V ., Leiden, the Netherlands   Business: Drug delivery, Cancer, Neurology   Date completed: 2014-06-30   Type: Venture financing   Raised: EUR10 million ($13.7 million)   Investors: New investors; existing investors  ...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Company News

to-BBB technologies B.V management update

to-BBB technologies B.V ., Leiden, the Netherlands   Business: Drug delivery, Cancer, Neurology   Hired: Pericles Calias as SVP of translational medicine, formerly senior director of nonclinical development of mRNA therapy at Shire plc  ...